Status:

RECRUITING

Hyperbaric Oxygen Therapy for Optic Neuropathies

Lead Sponsor:

Stanford University

Conditions:

Optic Neuropathy

Glaucoma

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The purpose of the study is to evaluate the neuroprotective efficacy of hyperbaric oxygen for the treatment in patients with optic neuropathy.

Eligibility Criteria

Inclusion

  • Patients must meet all of the following criteria to join the study (all eligibility criteria must be met at the screening and baseline visits unless otherwise noted):
  • Participant must be at least 18.
  • Participant must has the ability to comply with the requirements of the study and complete the schedule of events (SOE).
  • Participant's with clinical evidence of optic neuropathy.
  • Participant must understand and sign the informed consent. If the participant's vision is impaired to the point where he/she cannot read the informed consent document, the document will be read to the participant in its entirety.

Exclusion

  • Participant is unable to comply with study procedures or follow-up visits.
  • Participant has evidence of corneal opacification or lack of optical clarity.
  • Participant is currently participating in or has within the last 3 months participated in any other clinical trial of a drug by ocular (if in the study eye) or systemic administration.
  • Participant is pregnant or lactating.
  • Participant has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments.
  • Children and comatose patients.
  • Participant abusing drugs or alcohol.
  • Prior treatment with hyperbaric oxygen within the last 6 months.
  • Participant with claustrophobia or that cannot decompress properly.

Key Trial Info

Start Date :

November 1 2022

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2027

Estimated Enrollment :

60 Patients enrolled

Trial Details

Trial ID

NCT06128720

Start Date

November 1 2022

End Date

December 1 2027

Last Update

May 25 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Byers Eye Institute

Palo Alto, California, United States, 94303